Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.

Hirani, R; Hoad, V; Gosbell, IB; Irving, DO

Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.

Hirani, R Hoad, V Gosbell, IB Irving, DO

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Transfusion, 2022, 62, (2), pp. 292-297
Issue Date:: 2022-02

Closed Access

	Filename	Description	Size
	Transfusion - 2021 - Hirani - Absence of correlation between ABO Rh D blood group and neutralizing antibody titers in.pdf		431.49 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Hirani, R
dc.contributor.author	Hoad, V
dc.contributor.author	Gosbell, IB
dc.contributor.author	Irving, DO
dc.date.accessioned	2023-06-28T02:05:15Z
dc.date.available	2021-12-08
dc.date.available	2023-06-28T02:05:15Z
dc.date.issued	2022-02
dc.identifier.citation	Transfusion, 2022, 62, (2), pp. 292-297
dc.identifier.issn	0041-1132
dc.identifier.issn	1537-2995
dc.identifier.uri	http://hdl.handle.net/10453/170924
dc.description.abstract	BACKGROUND: Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are over-represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS-CoV-2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS-CoV-2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. STUDY DESIGN AND METHODS: ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. RESULTS: The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over-represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). CONCLUSION: ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS-CoV-2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Transfusion
dc.relation.isbasedon	10.1111/trf.16781
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1107 Immunology
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.mesh	ABO Blood-Group System
dc.subject.mesh	Animals
dc.subject.mesh	Antibodies, Neutralizing
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Australia
dc.subject.mesh	Blood Donors
dc.subject.mesh	COVID-19
dc.subject.mesh	Chlorocebus aethiops
dc.subject.mesh	Humans
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	Neutralization Tests
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Vero Cells
dc.subject.mesh	COVID-19 Serotherapy
dc.subject.mesh	Vero Cells
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	ABO Blood-Group System
dc.subject.mesh	Neutralization Tests
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	Blood Donors
dc.subject.mesh	Australia
dc.subject.mesh	Antibodies, Neutralizing
dc.subject.mesh	Chlorocebus aethiops
dc.subject.mesh	COVID-19
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	COVID-19 Serotherapy
dc.subject.mesh	ABO Blood-Group System
dc.subject.mesh	Animals
dc.subject.mesh	Antibodies, Neutralizing
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Australia
dc.subject.mesh	Blood Donors
dc.subject.mesh	COVID-19
dc.subject.mesh	Chlorocebus aethiops
dc.subject.mesh	Humans
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	Neutralization Tests
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Vero Cells
dc.subject.mesh	COVID-19 Serotherapy
dc.title	Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
dc.type	Journal Article
utslib.citation.volume	62
utslib.location.activity	United States
utslib.for	1102 Cardiorespiratory Medicine and Haematology
utslib.for	1103 Clinical Sciences
utslib.for	1107 Immunology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2023-06-28T02:05:14Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	62
utslib.citation.issue	2

Abstract:

BACKGROUND: Several studies have described associations between ABO blood group and SARS-CoV-2 infection severity in hospitalized patients where group A individuals are over-represented and group O individuals may have a lower infection rate. In convalescent individuals, group B blood donors have higher neutralizing SARS-CoV-2 antibody titers. We analyzed whether there was any correlation of ABO Rh(D) blood group with SARS-CoV-2 infection and with neutralizing antibodies in Australian convalescent plasma (CP) donors. STUDY DESIGN AND METHODS: ABO Rh(D) distribution and demographics of CP donors (n = 765) were compared with the total blood donor panel (n = 488,028), plasmapheresis donors (n = 203,176) and whole blood donors (n = 282,437) from 2020. The presence of neutralizing antibodies in CP donors was measured using the Vero E6 cell microneutralization assay. RESULTS: The distribution of ABO group in CP donors compared to the total donor panel was not significantly different (p = .177). There were significantly more group AB donors in the plasmapheresis subset (p = .005) and group O individuals were over-represented in the whole blood donor subset (p < .0001). There was no significant difference in neutralizing antibody levels among CP donors with differing ABO blood groups (p = .872). CONCLUSION: ABO Rh(D) blood group distribution was not found to be significantly different between convalescent plasma donors and general blood donors in our large sample group. Inherent blood donor selection biases associated with clinical demand accounted for some differences within CP donors. The levels of SARS-CoV-2 neutralizing antibodies were also not significantly associated with ABO Rh(D) group.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/170924